Advertisement

Related Videos

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Amit Sanyal, MD: A Clinician’s Perspective

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Advertisement

Advertisement




May
16
Today In Oncology
AACR Cancer Disparities Progress Report 2024 Highlights Ongoing Health Inequities Experienced by Racial and Ethnic Minorities
Previously Untreated Mantle Cell Lymphoma Ibrutinib, Immunochemotherapy, and ASCT
Marker for Distinguishing Renal Cell Carcinoma From Benign Renal Masses
FDA Approves HPV Self-Collection Solution
Disparities in Melanoma Outcomes Among Black Patients
View More 
Advertisement
© 2024 HSP News Service, L.L.C.
Designed by Harborside